Biogen shares drop as big clinics announce they won't administer controversial Alzheimer's drug

Cleveland Clinic and Mt. Sinai won't administer Aduhelm, a controversial but recently FDA-approved Alzheimer's drug. Both clinics issued statements which said they have problems with the FDA approval process for the drug.